CA2216601A1 - Intracellular domain of the her-2/neu protein for prevention or treatment of malignancies - Google Patents

Intracellular domain of the her-2/neu protein for prevention or treatment of malignancies

Info

Publication number
CA2216601A1
CA2216601A1 CA002216601A CA2216601A CA2216601A1 CA 2216601 A1 CA2216601 A1 CA 2216601A1 CA 002216601 A CA002216601 A CA 002216601A CA 2216601 A CA2216601 A CA 2216601A CA 2216601 A1 CA2216601 A1 CA 2216601A1
Authority
CA
Canada
Prior art keywords
malignancies
prevention
treatment
intracellular domain
neu protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002216601A
Other languages
French (fr)
Other versions
CA2216601C (en
Inventor
Martin A. Cheever
Mary L. Disis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University Of Washington
Martin A. Cheever
Mary L. Disis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Washington, Martin A. Cheever, Mary L. Disis filed Critical University Of Washington
Publication of CA2216601A1 publication Critical patent/CA2216601A1/en
Application granted granted Critical
Publication of CA2216601C publication Critical patent/CA2216601C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Abstract

Compounds and compositions for eliciting or enhancing immune reactivity to HER-2/neu protein are disclosed. The compounds include polypeptides and nucleic acid molecules encoding such peptides. The compounds may be used for the prevention or treatment of malignancies in which the HER-2/neu oncogene is associated.
CA002216601A 1995-03-31 1996-03-28 Intracellular domain of the her-2/neu protein for prevention or treatment of malignancies Expired - Fee Related CA2216601C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/414,417 US5801005A (en) 1993-03-17 1995-03-31 Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US08/414,417 1995-03-31
PCT/US1996/001689 WO1996030514A1 (en) 1995-03-31 1996-03-28 Intracellular domain of the her-2/neu protein for prevention or treatment of malignancies

Publications (2)

Publication Number Publication Date
CA2216601A1 true CA2216601A1 (en) 1996-10-03
CA2216601C CA2216601C (en) 2002-10-22

Family

ID=23641368

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002216601A Expired - Fee Related CA2216601C (en) 1995-03-31 1996-03-28 Intracellular domain of the her-2/neu protein for prevention or treatment of malignancies

Country Status (19)

Country Link
US (9) US5801005A (en)
EP (2) EP1418235A3 (en)
JP (2) JP4510147B2 (en)
KR (1) KR100554186B1 (en)
CN (3) CN1951398A (en)
AT (1) ATE299180T1 (en)
AU (1) AU708237B2 (en)
BR (1) BR9607889A (en)
CA (1) CA2216601C (en)
CZ (2) CZ296618B6 (en)
DE (1) DE69634912T2 (en)
DK (1) DK0817846T3 (en)
ES (1) ES2245783T3 (en)
HU (1) HUP9801826A3 (en)
NO (2) NO321941B1 (en)
NZ (1) NZ306616A (en)
PT (1) PT817846E (en)
RU (2) RU2236461C2 (en)
WO (1) WO1996030514A1 (en)

Families Citing this family (335)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
WO1996018409A1 (en) * 1994-12-14 1996-06-20 The Scripps Research Institute In vivo activation of tumor-specific cytotoxic t cells
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
BR9612619A (en) * 1996-05-15 1999-07-20 Altarex Inc Method and composition for reconforming multiepitopic antigens to initiate an immune response
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP0963435B1 (en) 1997-01-08 2008-05-28 Invitrogen Corporation Methods for production of proteins
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
NZ337054A (en) * 1997-01-30 2001-03-30 Chiron Corp Microparticles PLA and PLG with adsorbed viral antigen to stimulate immune responses particularly for intracellular viruses such as HSV-1 or HSV-2, varicella zoster virus. epstein-barr virus or cytomegalovirus (CMV)
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JP2002514573A (en) * 1998-05-08 2002-05-21 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Compositions and methods for active vaccination
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
NZ528199A (en) 1998-08-11 2005-06-24 Idec Pharma Corp Combination therapies for B-cell lyphomas comprising administration of anti-CD20 antibody
US6573043B1 (en) * 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
ES2338287T3 (en) * 1998-11-09 2010-05-05 Biogen Idec Inc. TREATMENT OF ANTI-CD20 PATIENTS ANTIBODIES RECEIVING TRANSPLANTS OF OSEA MEDULA GRAFT OR MOTHER PERIPHERAL BLOOD CELLS.
AU761844C (en) * 1998-11-09 2004-09-23 F. Hoffmann-La Roche Ag Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US6403630B1 (en) 1999-01-27 2002-06-11 Cornell Research Foundation, Inc. Treating cancers associated with overexpression of HER-2/neu
ES2348708T3 (en) * 1999-01-29 2010-12-13 Corixa Corporation FUSION PROTEINS OF HER-2 / NEU.
US7198920B1 (en) * 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
AU3755800A (en) * 1999-03-15 2000-10-04 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
EP1754488A1 (en) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
JP2003500041A (en) * 1999-05-25 2003-01-07 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド METH1 and METH2 polynucleotides and polypeptides
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
PT1189634E (en) * 1999-06-25 2007-06-06 Genentech Inc Treating prostate cancer with anti-erbb2 antibodies
US7060284B1 (en) * 1999-08-03 2006-06-13 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
MXPA02002037A (en) * 1999-08-27 2002-10-31 Genentech Inc DOSAGES FOR TREATMENT WITH ANTI ErbB2 ANTIBODIES.
US20030157119A1 (en) * 1999-09-22 2003-08-21 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
CA2383615A1 (en) * 1999-09-22 2001-03-29 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
EP1216055A2 (en) * 1999-09-30 2002-06-26 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US7378096B2 (en) 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
FR2801106B1 (en) * 1999-11-12 2007-10-05 Commissariat Energie Atomique METHOD FOR DIAGNOSING AN ATNC STRAIN-INDUCED TEST IN A BIOLOGICAL SAMPLE AND ITS USE IN THE DIFFERENTIAL DIAGNOSIS OF DIFFERENT ATNC STRAINS
JP2003530083A (en) * 1999-12-10 2003-10-14 エピミューン インコーポレイテッド Induction of a Cellular Immune Response to HER2 / neu Using Peptide and Nucleic Acid Compositions
WO2001048205A2 (en) * 1999-12-29 2001-07-05 Corixa Corporation Murine neu sequences and methods of use therefor
WO2001053463A2 (en) * 2000-01-21 2001-07-26 Corixa Corporation COMPOUNDS AND METHODS FOR PREVENTION AND TREATMENT OF HER-2/neu ASSOCIATED MALIGNANCIES
US6528060B1 (en) * 2000-03-16 2003-03-04 Genzyme Corporation Therapeutic compounds
WO2001074855A2 (en) * 2000-03-30 2001-10-11 Dendreon Corporation Compositions and methods for dendritic cell-based immunotherapy
US7166694B2 (en) * 2000-04-13 2007-01-23 Christoph Zielinski Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells
WO2001083781A2 (en) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
IL152656A0 (en) * 2000-05-19 2003-06-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US10293056B1 (en) 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
FR2812087B1 (en) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med METHOD OF SCREENING PEPTIDES USED IN IMMUNOTHERAPY
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
WO2002013847A2 (en) * 2000-08-14 2002-02-21 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
MXPA03001389A (en) * 2000-08-14 2004-05-04 Corixa Corp Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies.
KR100831139B1 (en) 2000-10-18 2008-05-20 글락소스미스클라인 바이오로지칼즈 에스.에이. Vaccines
WO2002045737A2 (en) * 2000-12-07 2002-06-13 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
ATE396691T1 (en) 2001-02-20 2008-06-15 Ortho Mcneil Pharm Inc CELL THERAPY PROCESS FOR THE TREATMENT OF TUMORS
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
ES2394293T3 (en) * 2001-02-28 2013-01-30 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Vaccine against cancers that are associated with the HER-2 / neu oncogene
EP2371854B1 (en) 2001-03-09 2014-05-07 Board Of Regents, The University Of Texas System Induction of tumor immunity by variants of folate binding protein
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
WO2002099035A2 (en) 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles
DE50111493D1 (en) * 2001-09-03 2007-01-04 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Antigen mimotope and vaccine against cancer
EP1438583B1 (en) 2001-09-20 2009-09-16 Board of Regents, The University of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
JP2005533000A (en) * 2002-03-05 2005-11-04 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム Method for enhancing immunity induction involving MDA-7
WO2003076585A2 (en) 2002-03-08 2003-09-18 Board Of Regents, The University Of Texas System Controlled modulation of amino acid side chain length of peptide antigens
CA2481796A1 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
AU2003251597A1 (en) * 2002-06-19 2004-01-06 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
KR101170653B1 (en) * 2002-08-12 2012-08-03 제네렉스, 인코포레이티드 Methods and compositions concerning poxviruses and cancer
US20080019992A1 (en) * 2002-09-02 2008-01-24 Christoph Zielinski Antigen mimotopes and vaccine against cancerous diseases
CN1497255A (en) * 2002-10-02 2004-05-19 ���µ�����ҵ��ʽ���� Sampling element for tested body, tested body processing device and its processing method
AU2003267077A1 (en) * 2002-11-12 2004-06-03 Millipore Corporation Evaporation control device for multiwell plates
GB2395270B (en) * 2002-11-14 2006-08-16 Univ Nottingham Tumour marker proteins and uses thereof
JP2006516117A (en) * 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド Treatment of non-malignant diseases or disorders using anti-ErbB2 antibodies
US7282365B2 (en) 2003-01-03 2007-10-16 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Rhesus HER2/neu, nucleotides encoding same, and uses thereof
US7638270B2 (en) * 2003-01-24 2009-12-29 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254P1D6B useful in treatment and detection of cancer
WO2004078124A2 (en) * 2003-03-03 2004-09-16 Board Of Regents, The University Of Texas System Methods and compositions involving mda-7
ES2456666T3 (en) 2003-04-18 2014-04-23 Biotech Synergy, Inc. HLA-A2 antigen peptides associated with a tumor and compositions
AU2004265226A1 (en) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
WO2004112825A2 (en) * 2003-06-17 2004-12-29 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
EP1649020B1 (en) * 2003-07-21 2017-01-11 MSD Italia S.r.l. Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
WO2005041656A2 (en) 2003-10-22 2005-05-12 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in tissues and organs
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
WO2005082396A2 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
US20060286102A1 (en) * 2004-05-14 2006-12-21 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
EP2471921A1 (en) 2004-05-28 2012-07-04 Asuragen, Inc. Methods and compositions involving microRNA
JP5234734B2 (en) 2004-06-01 2013-07-10 ジェネンテック， インコーポレイテッド Antibody-drug conjugates and methods
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
AU2005294347A1 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
CN101036055B (en) * 2004-10-06 2011-06-29 威尔斯达特生物制剂公司 Detection of elevated levels of Her-2/neu protein on circulating cancer cells and treatment
EP2302054B1 (en) 2004-11-12 2014-07-16 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US20060115862A1 (en) * 2004-11-17 2006-06-01 Duke University Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
CN100381460C (en) * 2004-11-30 2008-04-16 北京市肿瘤防治研究所 HER-2 analogue antigen epitope and peptide containing said epitope
US20060165711A1 (en) * 2004-12-29 2006-07-27 Bot Adrian I Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
US20070009484A1 (en) * 2005-02-08 2007-01-11 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
JP2008538569A (en) 2005-04-20 2008-10-30 フレッド ハッチンソン キャンサー リサーチ センター Methods, compositions, and articles of manufacture for enhancing the viability of cells, tissues, organs, and organisms
CN100398558C (en) * 2005-05-10 2008-07-02 中国人民解放军军事医学科学院基础医学研究所 Active segment of HER2/neu with Herstatin interaction, coding gene and application thereof
JP2008544962A (en) * 2005-05-12 2008-12-11 イントロゲン セラピューティックス， インコーポレイテッド P53 vaccine for the treatment of cancer
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
PT1889059E (en) 2005-05-27 2009-10-01 Oncimmune Ltd Improved immunoassay methods
AU2006261342B2 (en) 2005-06-15 2012-02-02 The Ohio State University Research Foundation Her-2 peptides
ES2413079T3 (en) 2005-06-17 2013-07-15 Mannkind Corporation Methods and compositions for triggering multivalent immune responses against dominant and subdominant epitopes expressed in cancer cells and tumor stroma
GB0512751D0 (en) * 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
CA2621982C (en) * 2005-09-07 2017-11-28 Jennerex Biotherapeutics Ulc Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
AU2006289683A1 (en) * 2005-09-07 2007-03-15 Receptor Logic, Ltd. Antibodies as T cell receptor mimics, methods of production and uses thereof
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
EP3195877A1 (en) * 2005-09-08 2017-07-26 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Targeted identification of immunogenic peptides
EP1945247A1 (en) 2005-10-18 2008-07-23 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
TWI457133B (en) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
EP1984004A4 (en) * 2006-01-17 2010-03-03 Sloan Kettering Inst Cancer Therapy-enhancing glucan
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
EP2010530A2 (en) * 2006-03-23 2009-01-07 Novartis AG Methods for the preparation of imidazole-containing compounds
CA2646891A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
US7517270B2 (en) * 2006-05-30 2009-04-14 Minds-I, Inc. Construction system
EP2069386A4 (en) 2006-07-21 2009-10-28 Life Technologies Corp Sharply resolving labeled protein molecular weight standards
US7972602B2 (en) 2006-08-11 2011-07-05 Dendreon Corporation Promiscuous HER-2/Neu CD4 T cell epitopes
US8574848B2 (en) * 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods
US8481023B2 (en) 2006-09-15 2013-07-09 Ottawa Hospital Research Institute Oncolytic rhabdovirus
CA2663962A1 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
US20080075528A1 (en) * 2006-09-22 2008-03-27 Michael Marzetta Construction system
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8097256B2 (en) * 2006-09-28 2012-01-17 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US20080131878A1 (en) * 2006-12-05 2008-06-05 Asuragen, Inc. Compositions and Methods for the Detection of Small RNA
WO2008073919A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention
US8889143B2 (en) 2006-12-14 2014-11-18 Antigen Express, Inc. Ii-key/HER-2/neu hybrid cancer vaccine
US7935350B2 (en) * 2006-12-14 2011-05-03 Antigen Express, Inc. Ii-key/Her-2/neu hybrid cancer vaccine
US7410225B1 (en) * 2007-03-14 2008-08-12 Minds-I, Inc. Multi-part links for endless track
KR20080084528A (en) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. Oncolytic vaccinia virus cancer therapy
WO2008130910A1 (en) * 2007-04-19 2008-10-30 Wellstat Biologics Corporation Detection her-2/neu protein from non-isolated circulating cancer cells and treatment
KR102079921B1 (en) 2007-06-01 2020-02-21 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 Vaccine for the prevention of breast cancer relapse
US20090017716A1 (en) * 2007-07-11 2009-01-15 Michael Marzetta Construction system
US20090061456A1 (en) * 2007-08-30 2009-03-05 Allard William J Method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US20090117532A1 (en) * 2007-11-01 2009-05-07 Doyle Gerald V Pre-clinical method for monitoring serial changes in circulating breast cancer cells in mice
WO2009059450A1 (en) * 2007-11-05 2009-05-14 Shanghai Jiaotong University Peptide ligand directed drug delivery
US7841923B2 (en) * 2007-11-13 2010-11-30 Minds-I, Inc. Vehicle axle joint for a toy vehicle
US20090136946A1 (en) 2007-11-27 2009-05-28 Mark Carle Connelly Automated Enumeration and Characterization of Circulating Melanoma Cells in Blood
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
US20090191535A1 (en) * 2007-12-22 2009-07-30 Mark Carle Connelly Method of assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
JP2010006705A (en) * 2008-06-13 2010-01-14 Atlas Antibodies Ab Her2 subset
EP2328923B1 (en) * 2008-09-02 2016-01-13 Cedars-Sinai Medical Center Cd133 epitopes
CN102245197A (en) 2008-12-10 2011-11-16 亨利·M·杰克逊军事医学促进基金会 Vaccine for the prevention of breast cancer recurrence
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
US20110045080A1 (en) * 2009-03-24 2011-02-24 William Marsh Rice University Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
NZ596468A (en) * 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
WO2010144874A2 (en) 2009-06-12 2010-12-16 University Of Southern California Clusterin pharmaceuticals and treatment methods using the same
US8470980B2 (en) 2009-09-09 2013-06-25 Centrose, Llc Extracellular targeted drug conjugates
KR101838472B1 (en) 2009-09-14 2018-03-15 신라젠(주) Oncolytic vaccinia virus combination cancer therapy
MX365946B (en) 2009-12-10 2019-06-19 Turnstone Lp Oncolytic rhabdovirus.
WO2011107100A1 (en) 2010-03-03 2011-09-09 Aarhus Universitet Methods and compositions for regulation of herv4
CA2793890C (en) 2010-04-15 2017-08-15 Spirogen Developments Sarl Pyrrolobenzodiazepines and conjugates thereof
EP2576613A1 (en) 2010-06-07 2013-04-10 Pfizer Inc. Her-2 peptides and vaccines
JP2013534520A (en) 2010-06-08 2013-09-05 ジェネンテック， インコーポレイテッド Cysteine engineered antibodies and conjugates
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
JP6121910B2 (en) 2011-01-04 2017-04-26 シラジェン バイオセラピューティクス インコーポレイテッド Generation of antibodies against tumor antigens and tumor-specific complement-dependent cytotoxicity by administration of oncolytic vaccinia virus
EP2670849A1 (en) 2011-02-03 2013-12-11 Mirna Therapeutics, Inc. Synthetic mimics of mir-124
MY165507A (en) 2011-02-03 2018-03-28 Mirna Therapeutics Inc Synthetic mimics of mir-34
EP2707723B1 (en) 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
US9364532B2 (en) 2011-06-08 2016-06-14 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions and methods for glioblastoma treatment
AU2012294814A1 (en) 2011-08-05 2014-02-27 Research Development Foundation Improved methods and compositions for modulation of Olfml3 mediated angiogenesis
SG10201903119QA (en) 2011-09-06 2019-05-30 Agency Science Tech & Res Polypeptide vaccine
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
MX350152B (en) 2011-10-14 2017-08-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof.
EP2814836B1 (en) * 2012-02-17 2017-11-08 Mayo Foundation For Medical Education And Research Methods and materials for generating cd8+ t cells having the ability to recognize cancer cells expressing a her2/neu polypeptide
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
US20150283233A1 (en) 2012-06-15 2015-10-08 Gencia Corporation Compositions and Methods for Enhancing Immune Responses
UA114108C2 (en) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
CN105050661B (en) 2012-10-12 2018-03-30 Adc疗法责任有限公司 Pyrrolobenzodiazepines Zhuo antibody conjugates
DK2906296T3 (en) 2012-10-12 2018-05-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
HUE045435T2 (en) 2012-10-12 2019-12-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
BR112015008173A2 (en) 2012-10-12 2017-11-28 Adc Therapeutics Sarl pyrrolobenzodiazepine-anti-psma antibody conjugates
SI2906251T1 (en) 2012-10-12 2018-01-31 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
ES2660029T3 (en) 2012-10-12 2018-03-20 Medimmune Limited Antibody-pyrrolobenzodiazepine conjugates
WO2014066590A1 (en) 2012-10-24 2014-05-01 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
AU2013366490B9 (en) 2012-12-21 2018-02-01 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
CA2894961C (en) 2012-12-21 2020-09-15 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
ES2662333T3 (en) 2013-02-14 2018-04-06 Immunocellular Therapeutics Ltd. Cancer vaccines and vaccination methods
RU2684211C2 (en) 2013-02-21 2019-04-04 Тёрнстоун Лимитед Партнершип Vaccine composition
WO2014140174A1 (en) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
AU2014244245C1 (en) 2013-03-13 2018-04-19 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
WO2014140862A2 (en) 2013-03-13 2014-09-18 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
TWI636792B (en) 2013-08-12 2018-10-01 建南德克公司 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
KR20160068738A (en) 2013-08-14 2016-06-15 윌리엄 마쉬 라이스 유니버시티 Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
EP3036005A4 (en) 2013-08-21 2017-04-26 The Board Of Regents Of The University Of Texas System Compositions and methods for targeting connexin hemichannels
WO2015031735A1 (en) 2013-08-29 2015-03-05 Board Of Regents, The University Of Texas System Engineered primate cystine/cysteine degrading enzymes as antineogenic agents
CN113957061A (en) 2013-08-30 2022-01-21 得克萨斯大学体系董事会 Administration of kynurenine depleting enzymes for tumor therapy
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2015085096A1 (en) 2013-12-04 2015-06-11 Board Of Regents, The University Of Texas System Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
CN105873614B (en) 2013-12-16 2020-10-30 基因泰克公司 Peptidomimetic compounds and antibody-drug conjugates thereof
EA201691023A1 (en) 2013-12-16 2016-10-31 Дженентек, Инк. PEPTIDOMIMETIC CONNECTIONS AND THEIR CONJUGATES ANTIBODIES WITH MEDICINE
MX2016007578A (en) 2013-12-16 2016-10-03 Genentech Inc 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.
WO2016153761A1 (en) * 2015-03-13 2016-09-29 Czerniecki Brian J Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
WO2016190940A1 (en) * 2015-05-22 2016-12-01 Czerniecki Brian J Manufacturing multi-dose injection ready dendritic cell vaccines
WO2016033105A1 (en) 2014-08-29 2016-03-03 The Board Of Regents Of The University Of Texas System Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
EP3186371A4 (en) 2014-08-29 2018-01-10 Board of Regents, The University of Texas System Administration of kynurenine depleting enzymes for tumor therapy
JP6531166B2 (en) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugate
AR101844A1 (en) 2014-09-12 2017-01-18 Genentech Inc ANTIBODIES AND GENETICALLY MODIFIED CONJUGATES WITH CYSTEINE
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3191134B1 (en) 2014-09-12 2019-11-20 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
EP3194400A1 (en) 2014-09-17 2017-07-26 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
BR112017011111A2 (en) 2014-11-25 2017-12-26 Adc Therapeutics Sa pyrrolobenzodiazepine-antibody conjugates
KR20170086121A (en) 2014-12-03 2017-07-25 제넨테크, 인크. Quaternary amine compounds and antibody-drug conjugates thereof
AU2016219511B2 (en) 2015-02-09 2020-11-12 Research Development Foundation Engineered immunoglobulin Fc polypeptides displaying improved complement activation
MX2017011298A (en) 2015-03-04 2018-06-19 Univ Texas Methods of treating cancer harboring hemizygous loss of tp53.
US20180171294A1 (en) * 2015-03-26 2018-06-21 The Trustees Of The University Of Pennsylvania In vitro artificial lymph node method for sensitization and expansion of t cells for therapy and epitope mapping
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
US9993538B2 (en) 2015-05-29 2018-06-12 Galena Biopharma, Inc. Peptide vaccine therapy for treatment of FRα-expressing tumors
EP3307890A1 (en) 2015-06-10 2018-04-18 Board of Regents, The University of Texas System Use of exosomes for the treatment of disease
RU2612015C2 (en) * 2015-06-29 2017-03-01 Общество с ограниченной ответственностью "Сибинтех" Peptide-immunogen used in therapeutic vaccine for treatment of metastatic breast cancer of cats and dogs
WO2017019829A1 (en) 2015-07-28 2017-02-02 Board Of Regents, The University Of Texas System Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
US10526408B2 (en) 2015-08-28 2020-01-07 Research Development Foundation Engineered antibody FC variants
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
KR20180091816A (en) 2015-10-14 2018-08-16 바이오-패쓰 홀딩스 인크. P-ethoxy nucleic acid for liposome preparation
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
RU2624862C2 (en) * 2015-10-20 2017-07-07 Общество с ограниченной ответственностью "Эпитек" Peptide-immunogen used in therapeutic vaccine for metastatic breast cancer treatment
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
CN108884159A (en) 2015-11-07 2018-11-23 茂体外尔公司 The composition use for cancer treatment blocked comprising tumor suppressor gene treatment and immunologic test point
AU2016354440B2 (en) 2015-11-09 2023-09-28 The Children's Hospital Of Philadelphia Glypican 2 as a cancer marker and therapeutic target
CN109415437B (en) 2015-12-02 2022-02-01 斯特库伯株式会社 Antibodies and molecules that immunospecifically bind to BTN1A1 and therapeutic uses thereof
CN108925136B (en) 2015-12-02 2022-02-01 斯特赛恩斯公司 Antibodies specific for glycosylated BTLA (B and T lymphocyte attenuating factor)
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US10889637B2 (en) 2016-02-26 2021-01-12 The Board Of Regents Of The University Of Texas System Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies
MX2018010586A (en) 2016-03-02 2019-03-28 Univ Texas Sting activating nanovaccine for immunotherapy.
JP6943872B2 (en) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド Multiple whole antibody and antibody complex drug quantification assay
CN109195991B (en) 2016-03-29 2023-10-31 斯特库比股份有限公司 Dual function antibodies specific for glycosylated PD-L1 and methods of use thereof
KR20230031373A (en) 2016-03-29 2023-03-07 주식회사 에스티큐브앤컴퍼니 Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
WO2017189976A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PL3458101T3 (en) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Protac antibody conjugates and methods of use
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
WO2017210255A1 (en) 2016-05-31 2017-12-07 Galena Biopharma, Inc. Vaccine therapy for treatment of endometrial and ovarian cancer
AU2017273878A1 (en) * 2016-06-03 2019-01-03 Etubics Corporation Compositions and methods for tumor vaccination and immunotherapy involving HER2/neu
WO2017214024A1 (en) 2016-06-06 2017-12-14 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
KR20190026813A (en) 2016-07-06 2019-03-13 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Human-enzyme mediated depletion of cystine
KR20190031299A (en) 2016-07-20 2019-03-25 주식회사 에스티큐브 Methods of treating cancer using a combination of antibodies that bind to glycosylated PD-L1
CN109689111B (en) 2016-08-11 2024-04-05 基因泰克公司 Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018035429A1 (en) 2016-08-18 2018-02-22 Wisconsin Alumni Research Foundation Peptides that inhibit syndecan-1 activation of vla-4 and igf-1r
US10927379B2 (en) 2016-09-16 2021-02-23 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
EP3538112A4 (en) 2016-11-09 2020-09-02 Musc Foundation for Research Development Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
WO2018111902A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
DK3544636T3 (en) 2017-02-08 2021-05-10 Adc Therapeutics Sa Pyrrolobenzodiazepine antibody conjugates
JP7162398B2 (en) 2017-02-24 2022-10-28 ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム Early pancreatic cancer detection assay
DK3612537T3 (en) 2017-04-18 2022-08-08 Medimmune Ltd PYRROLOBENZODIAZEPIN CONJUGATES
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
US10865403B2 (en) 2017-05-12 2020-12-15 Board Of Regents, The University Of Texas System Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
CA3060988A1 (en) 2017-05-12 2018-11-15 Board Of Regents, The University Of Texas System Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria
CN111051346A (en) 2017-05-31 2020-04-21 斯特库伯株式会社 Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1a1
CA3065301A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
US11542331B2 (en) 2017-06-06 2023-01-03 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands
KR102442736B1 (en) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 Dosage regime for administration of anti-CD19 ADCs
KR102312910B1 (en) 2017-08-18 2021-10-15 메디뮨 리미티드 Pyrrolobenzodiazepine conjugates
TW201920192A (en) 2017-09-20 2019-06-01 韓商Ｐｈ製藥公司 THAILANSTATIN analogs
EP3694545A4 (en) 2017-10-11 2021-12-01 Board Of Regents, The University Of Texas System Human pd-l1 antibodies and methods of use therefor
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
WO2020036635A2 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
US20210214445A1 (en) 2018-03-23 2021-07-15 Board Of Regents, The University Of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN108624589B (en) * 2018-04-17 2021-12-17 广州永诺生物科技有限公司 Circular RNA circ-ERBB2, detection reagent and application thereof
CN108715603A (en) * 2018-06-08 2018-10-30 天津亨佳生物科技发展有限公司 A kind of Antigenic Peptide chain group for treating tumour and its application in drug
CN108484732A (en) * 2018-06-08 2018-09-04 天津亨佳生物科技发展有限公司 A kind of Antigenic Peptide chain group for treating tumour and its application in drug
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CN113056287A (en) 2018-10-24 2021-06-29 豪夫迈·罗氏有限公司 Conjugated chemical degradation inducers and methods of use
US20220033848A1 (en) 2018-11-19 2022-02-03 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
AU2019386140A1 (en) 2018-11-28 2021-06-24 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
US20220033778A1 (en) 2018-11-29 2022-02-03 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
WO2020163705A1 (en) 2019-02-08 2020-08-13 Board Of Regents, The University Of Texas System Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
CA3138348A1 (en) 2019-05-09 2020-11-12 FUJIFILM Cellular Dynamics, Inc. Methods for the production of hepatocytes
CA3139162A1 (en) 2019-05-17 2020-11-26 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis
AU2020317009A1 (en) 2019-07-19 2022-02-03 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptors containing Glypican 2 binding domains
AU2020344675A1 (en) 2019-09-13 2022-03-31 Elektrofi, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
WO2021062323A1 (en) 2019-09-26 2021-04-01 Stcube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
JP2022552282A (en) 2019-10-09 2022-12-15 エスティーキューブ アンド カンパニー Antibodies specific for glycosylated LAG3 and methods of use thereof
US20220380765A1 (en) 2019-11-02 2022-12-01 Board Of Regents, The University Of Texas System Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
JP2023509516A (en) 2020-01-07 2023-03-08 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Improved human methylthioadenosine/adenosine-depleting enzyme variants for cancer therapy
CA3168337A1 (en) 2020-02-17 2021-08-26 Marie-Andree Forget Methods for expansion of tumor infiltrating lymphocytes and use thereof
US20230212256A1 (en) 2020-05-21 2023-07-06 Board Of Regents, The University Of Texas System T cell receptors with vgll1 specificity and uses thereof
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
EP4172370A1 (en) 2020-06-30 2023-05-03 Lunglife Ai, Inc. Methods for detecting lung cancer
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
EP4251645A1 (en) 2020-11-25 2023-10-04 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
EP4281116A1 (en) 2021-01-19 2023-11-29 William Marsh Rice University Bone-specific delivery of polypeptides
GB2603166A (en) 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
CA3228262A1 (en) 2021-08-04 2023-02-09 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
WO2023020612A1 (en) * 2021-08-20 2023-02-23 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric her2
WO2023060136A1 (en) 2021-10-05 2023-04-13 Cytovia Therapeutics, Llc Natural killer cells and methods of use thereof
CN113699221B (en) * 2021-10-19 2023-10-10 广州吉赛医疗科技有限公司 HER2 mRNA and annular RNA multiplex fluorescence quantitative PCR detection primer probe and application thereof
WO2023068382A2 (en) 2021-10-20 2023-04-27 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
WO2023076880A1 (en) 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
CN114262689A (en) * 2021-12-17 2022-04-01 上海纳米技术及应用国家工程研究中心有限公司 Method for rapidly detecting activity of CD19/CD20-CAR-T cells
GB202201137D0 (en) 2022-01-28 2022-03-16 Thelper As Therapeutic and diagnostic agents and uses thereof
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
WO2023192976A1 (en) 2022-04-01 2023-10-05 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2023220083A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
WO2023230531A1 (en) 2022-05-24 2023-11-30 Lunglife Ai, Inc. Methods for detecting circulating genetically abnormal cells
WO2023239940A1 (en) 2022-06-10 2023-12-14 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) * 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) * 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3901654A (en) * 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3766162A (en) * 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US3935074A (en) * 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) * 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) * 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) * 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4233402A (en) * 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4452901A (en) * 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
EP0474727B1 (en) * 1989-05-19 1997-07-23 Genentech, Inc. Her2 extracellular domain
CA2042064C (en) * 1989-08-04 2008-10-21 Susan G. Stuart C-erbb-2 external domain:gp75
DE69131255T2 (en) * 1990-01-26 1999-12-16 Washington Res Found Immunoreactivity to expressed activated oncogenes for the diagnosis and treatment of malignant tumors
US5958784A (en) * 1992-03-25 1999-09-28 Benner; Steven Albert Predicting folded structures of proteins
CN1118572A (en) * 1993-03-05 1996-03-13 萨依特尔有限公司 HLA-A2.1 combined peptide and application of same
US5550214A (en) * 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
WO1996018409A1 (en) * 1994-12-14 1996-06-20 The Scripps Research Institute In vivo activation of tumor-specific cytotoxic t cells
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
FR2812087B1 (en) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med METHOD OF SCREENING PEPTIDES USED IN IMMUNOTHERAPY

Also Published As

Publication number Publication date
EP1418235A2 (en) 2004-05-12
NZ306616A (en) 2001-03-30
HUP9801826A3 (en) 2000-12-28
PT817846E (en) 2005-11-30
US6075122A (en) 2000-06-13
US7247703B2 (en) 2007-07-24
US20080076904A1 (en) 2008-03-27
EP0817846A1 (en) 1998-01-14
US5846538A (en) 1998-12-08
HUP9801826A2 (en) 1998-11-30
DK0817846T3 (en) 2005-11-07
US5801005A (en) 1998-09-01
RU2004115492A (en) 2005-11-10
RU2236461C2 (en) 2004-09-20
US20020055614A1 (en) 2002-05-09
CZ296618B6 (en) 2006-05-17
JP2008056679A (en) 2008-03-13
NO321941B1 (en) 2006-07-24
DE69634912D1 (en) 2005-08-11
CA2216601C (en) 2002-10-22
CN1150318C (en) 2004-05-19
DE69634912T2 (en) 2006-04-20
US5876712A (en) 1999-03-02
EP1418235A3 (en) 2004-08-11
US7655239B2 (en) 2010-02-02
BR9607889A (en) 1999-08-10
US20100087621A1 (en) 2010-04-08
US6664370B2 (en) 2003-12-16
AU5522296A (en) 1996-10-16
MX9707501A (en) 1998-06-30
ES2245783T3 (en) 2006-01-16
CN1183117A (en) 1998-05-27
EP0817846B1 (en) 2005-07-06
CZ296617B6 (en) 2006-05-17
NO20061723L (en) 1996-10-01
NO974502L (en) 1997-11-27
CZ309697A3 (en) 1998-01-14
ATE299180T1 (en) 2005-07-15
AU708237B2 (en) 1999-07-29
KR19980703453A (en) 1998-11-05
US5726023A (en) 1998-03-10
JPH11502710A (en) 1999-03-09
WO1996030514A1 (en) 1996-10-03
CN1951398A (en) 2007-04-25
KR100554186B1 (en) 2007-04-11
NO974502D0 (en) 1997-09-29
US20040082758A1 (en) 2004-04-29
JP4510147B2 (en) 2010-07-21
CN1597953A (en) 2005-03-23

Similar Documents

Publication Publication Date Title
CA2216601A1 (en) Intracellular domain of the her-2/neu protein for prevention or treatment of malignancies
WO1998021328A3 (en) Human proteins having transmembrane domains and dnas encoding these proteins
CA2102208A1 (en) Binding domains in notch and delta proteins
AU9795098A (en) 2,3-benzodiazepin-2-one derivatives, their preparation and their use as inhibi tors of protein tyrosine kinases
UA39158C2 (en) derivatives of N4-oxycarbonyl- 5'-deoxy-5-fluorocytidine and pharmaceutical preparation based thereon
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
HUP9901688A3 (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
WO1999014241A3 (en) Compositions and methods for the treatment of immune related diseases
NZ330400A (en) Novel dna and process for preparing 60 to 120 kd proteins capable of inhibiting the formation of osteoclasts using said dna
AU4263696A (en) Peptides capable of binding to the gap protein sh3 domain, nucleotide sequences coding therefor, and preparation and use thereof
EP0319315A3 (en) The von willebrand factor binding domain of factor viii
AU5508396A (en) Pcna binding substance
EP1146124A3 (en) Gustducin materials and methods
AU3711597A (en) A novel galanin receptor
DE69603530T2 (en) Process for the preparation of 1,1-difluoroethane
CA2193384A1 (en) Use of gabapentin in the treatment of anxiety and panic
WO2000015797A3 (en) Compositions and methods for the treatment of immune related diseases
DE69424503T2 (en) Process for the preparation of dimethylchlorosilane and triorganochlorosilane
CA2210871A1 (en) Human dnase i variants
DE69626171D1 (en) Process for the preparation of 1-substituted tetrahydroquinazoline dions
AU3651997A (en) Constructs and complexes of cyclin e
CA2247998A1 (en) Fragments of cr1 and their use
DE59603908D1 (en) Process for the preparation of N ', N'-disubstituted 1,4-diaminoanthraquinones
EP0292302A3 (en) Human splenin

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160329